Skip to main content
Clinical Trials/EUCTR2005-003138-16-GB
EUCTR2005-003138-16-GB
Active, not recruiting
Phase 1

A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates. - Strontium following bisphosphonate therapy

R+ D department, Hull and East Yorkshire NHS Hospital Trust0 sites0 target enrollmentJuly 25, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Postmenopausal Osteoporosis
Sponsor
R+ D department, Hull and East Yorkshire NHS Hospital Trust
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 25, 2005
End Date
July 31, 2009
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
R+ D department, Hull and East Yorkshire NHS Hospital Trust

Eligibility Criteria

Inclusion Criteria

  • 1\) \- Age: 50\-75
  • 2\) \- T score: \<\-2\.5 at either hip or spine or a T score \<2\.0 and one BMD independent risk factor for fracture (previous osteoporotic fracture, maternal osteoporotic fracture, previous steroid use, BMI \<19, untreated premature menopause) (typical criteria for patients considered as requiring treatment to reduced their risk of fracture).
  • 3\)\-Fit into group 1 or 2 below:
  • Group1: no previous bisphosphonates.
  • Group 2: \> 1 year treatment with oral bisphosphonates and stopped treatment within the last 1 month due to lack of effect or side effects. Also if treated with pamidronate for \> 1 year and last infusion within the last 3 month. (to allow clear distinction between the study groups)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Significant renal disease. (creatinine clearance \< 30 ml/min)
  • Prior treatment with Strontium Ranelate.
  • Active malignancy
  • Osteomalacia
  • Primary hyperparathyroidism
  • Patient is unable to give informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials